You are here

Article Text

Article menu
Download PDFPDF
Research paper
Serum homocysteine levels in relation to clinical progression in multiple sclerosis
  1. C E Teunissen1,
  2. J Killestein2,
  3. J J Kragt2,
  4. C H Polman2,
  5. C D Dijkstra1,
  6. H J Blom3
  1. 1
    Department of Molecular Cell Biology and Immunology, MS Centre Amsterdam, VU University Medical Centre Amsterdam, The Netherlands
  2. 2
    Department of Neurology, MS Centre Amsterdam, VU University Medical Centre Amsterdam, The Netherlands
  3. 3
    Department of Clinical Chemistry, VUmc Medical Centre Amsterdam, The Netherlands
  1. Dr C E Teunissen, Molecular Cell Biology and Immunology, VU University Medical Centre, FdG, PO Box 7057, 1007 MB Amsterdam, The Netherlands; c.teunissen{at}vumc.nl

Abstract

Background: Elevated homocysteine levels are associated with various neurodegenerative diseases and have even been identified as a risk factor for some of these. Homocysteine levels may be elevated in patients with multiple sclerosis (MS) but large studies are lacking and the relation with disease progression remains to be determined.

Aim: The aim of the study was to investigate homocysteine levels in patients with MS and in controls, and to study the relationship between homocysteine levels and clinical progression in MS.

Methods: Serum homocysteine levels were compared between MS subtypes (n = 219) and controls (n = 152). Homocysteine levels were associated with baseline and follow-up clinical severity scores.

Results: The results showed that serum homocysteine values were similar in patients with MS and controls. Baseline scores on the Expanded Disability Status Scale were higher in patients with secondary progressive MS (SPMS) in the top compared with the bottom quartile of homocysteine levels (p = 0.02). The baseline scores on the Multiple Sclerosis Functional Composite (MSFC) and Paced Auditory Serial Addition Test (PASAT), which measures cognitive functioning, were lower in patients with SPMS in the top compared with the bottom quartile of homocysteine levels (MSFC, p = 0.02; PASAT, p = 0.02). High homocysteine levels were associated with a decline in PASAT scores during follow-up in patients with primary progressive MS (p = 0.009).

Conclusion: Serum total homocysteine levels are associated with several measures of disease progression in MS but are not elevated in patients with MS compared with controls. The association of homocysteine levels with cognition in patients with progressive MS raises the question of whether homocysteine directly impacts on MS or reflects a more general neurodegenerative process.

https://doi.org/10.1136/jnnp.2008.151555

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Funding: This study was financially supported by The Dutch Research Council (NWO/VENI (016.056.024) and the J Dekker and L Bouwman Foundation. These foundations were not involved in any activities of the study, including design, conduct and completion of the study and manuscript.

    • Competing interests: None.

    • Ethics approval: Approval was obtained from the local ethics committee.